drugset / Trial / NCT06760182
Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis
Phase 2
Completed
169 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.
Timeline
- Start
- 2025-03-10
- Primary completion
- 2025-04-30
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQH2722 | Monoclonal antibody | — | — |